Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase I Dose-Escalation Study of CPI-613 (Devimistat) in Combination With Chemoradiation in Patients With Pancreatic Adenocarcinoma

Summary

The purpose of this phase I study is to evaluate the safety and tolerability of CPI-613 in combination with gemcitabine and radiation therapy (Gem-RT) in patients with pancreatic adenocarcinoma.

General Information

NCT#: NCT05325281
Study ID: PRO00043904
Trial Phase: Phase I

Trial Sponsor: Cornerstone Pharmaceuticals, Medical College of Wisconsin
Therapies Used in This Trial: Gemcitabine, Radiation Therapy, CPI-613

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search